Table 1 Characteristics of Patient Cohort
From: Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma
Patient no. | Age/sex | Stage | TNM | Total nodes/SNT | Positive nodes/SNP | IDO NH | IDO NS | Outcome |
|---|---|---|---|---|---|---|---|---|
1 | 42/F | IIIC | T4bN3M0 | 35/0 | 14/0 | 3+ | 0.76 | ANED/21 mos |
2 | 53/F | IIIC | T4aN3M0 | 7/0 | 1/0 (s) | N | 0.00 | AWD/16 mos |
3 | 60/M | IIIC | T4bN3M0 | 17/0 | 7/0 | 2+ | 0.43 | ANED/73 mos |
4 | 63/M | IIIC | T3aN3M0 | 20/0 | 5/0 | 4+ | 2.24 | DOD/22 mos |
5 | 75/M | IIIC | T3aN3M0 | 13/3 | 7/3 | 4+ | 1.92 | ANED/31 mos |
6 | 42/F | IIIC | T2xN3M0 | 19/1 | 1/1 (s) | 4+ | 0.37 | ANED/22 mos |
7 | 51/M | IIIC | TxN3M0a | 7/1 | 4/0 | 1+ | 0.50 | AWD/29 mos |
8 | 62/M | IIIB | T4aN2bM0 | 8/0 | 2/0 | 4+ | 2.31 | DUD/7 mos |
9 | 68/M | IIIB | T3aN2bM0 | 13/0 | 2/0 | 4+ | 2.41 | DOD/31 mos |
10 | 37/F | IIIA | T4aN2aM0 | 18/1 | 3/1 | 1+ | 1.62 | DOD/17 mos |
11 | 59/M | IIIX | T3xN2bM0 | 13/0 | 2/0 | N | 0.00 | DOD/20 mos |
12 | 40/M | IIIX | T2xN2bM0 | 14/0 | 2/0 | 4+ | 1.38 | ANED/45 mos |
13 | 45/M | IIIX | T2xN2bM0 | 21/0 | 3/0 | 1+ | 0.30 | ANED/10 mos |
14 | 44/F | IIIX | T4xN1bM0 | 24/0 | 1/0 | 1+ | 0.28 | DFOD/51 mos |
15 | 29/M | IIIX | T3xN1bM0 | 8/0 | 1/0 | 4+ | 1.38 | ANED/7 mos |
16 | 45/M | IIC | T4bN0M0 | 2/2 | 0/0 | 2+ | 1.00 | ANED/9 mos |
17 | 30/M | IIC | T4bN0M0 | 3/3 | 0/0 | 3+ | 2.00 | DOD/34 mos |
18 | 45/M | IIB | T4aN0M0 | 24/0 | 0/0 | 4+ | 1.25 | DOD/53 mos |
19 | 45/F | IIA | T3aN0M0 | 13/0 | 0/0 | 4+ | 1.96 | AWD/54 mos |
20 | 76/M | IIA | T3aN0M0 | 13/0 | 0/0 | 4+ | 1.08 | ANED/63 mos |
21 | 55/M | IIA | T3aN0M0 | 12/0 | 0/0 | 2+ | 0.13 | DUD/21 mos |
22 | 51/F | IIX | T3xN0M0 | 12/0 | 0/0 | 2+ | 0.38 | ANED/29 mos |
23 | 54/M | IIX | T3xN0M0 | 4/4 | 0/0 | N | 0.00 | ANED/21 mos |
24 | 26/F | IIX | T3xN0M0 | 2/2 | 0/0 | 2+ | 1.25 | ANED/26 mos |
25 | 35/M | IA | T1aN0M0 | 4/4 | 0/0 | 3+ | 0.63 | ANED/21 mos |
26 | 67/M | IX | TxN0M0b | 1/1 | 0/0 | N | 0.00 | ANED/22 mos |
